AirSculpt Technologies (NASDAQ:AIRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• AirSculpt beat estimates by $0.01, reporting EPS of ($0.01) vs. consensus ($0.02) and revenue of $39.4 million (flat YoY), while delivering its first positive same‑center sales in over two years (same‑store +~1% ex‑London, 19% sequential improvement).
• The balance sheet strengthened with $16.7 million in cash, $11 million of debt repaid (gross debt ~$46 million, leverage below 2.5x) and management in covenant compliance, and the company reaffirmed FY26 guidance of $151M–$157M revenue and $15M–$17M adjusted EBITDA while prioritizing same‑center growth.
• Management flagged a large long‑term opportunity from GLP‑1 drug adoption and is piloting skin‑tightening/removal services (150 skin excisions in Q1) that could potentially unlock more than $100M across centers, though these services are not yet a meaningful revenue driver.

AirSculpt Technologies (NASDAQ:AIRS - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01, FiscalAI reports. The company had revenue of $39.39 million during the quarter, compared to analyst estimates of $39.20 million. AirSculpt Technologies had a negative net margin of 7.68% and a negative return on equity of 5.01%.

Here are the key takeaways from AirSculpt Technologies' conference call:

• AirSculpt reported $39.4 million in Q1 revenue (flat YoY) and achieved its first positive same-center sales in over two years, with same-store revenue up ~1% excluding London and a 19% sequential improvement.
• Gross margin expanded to about 60% (cost of services $15.6M), but adjusted EBITDA fell to $3.3 million (8.4% of revenue) as SG&A rose roughly $0.8M due to deliberate marketing investments.
• The balance sheet strengthened—cash of $16.7 million, $11 million of debt repaid in the quarter, gross debt of ~$46 million, leverage below 2.5x, and management is working on a term‑loan refinance while remaining in covenant compliance.
• Management highlighted a large long‑term opportunity from GLP-1 drug adoption (projected growth to 25M users by 2030) and is piloting skin‑tightening and skin‑removal procedures (150 skin excisions in Q1) that could unlock an estimated >$100M across centers, though these services are not yet a meaningful revenue driver.
• The company reaffirmed FY26 guidance of $151M–$157M in revenue and $15M–$17M in adjusted EBITDA, expects sequential improvement in Q2, and does not plan any de novo center openings in 2026 while prioritizing same‑center growth.

AirSculpt Technologies Trading Down 0.8%

Shares of AirSculpt Technologies stock traded down $0.03 during mid-day trading on Friday, hitting $3.43. The stock had a trading volume of 1,677,564 shares, compared to its average volume of 2,345,654. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 0.58. The firm has a market cap of $242.20 million, a P/E ratio of -18.05 and a beta of 1.99. The firm has a 50-day moving average of $2.57 and a two-hundred day moving average of $3.51. AirSculpt Technologies has a 12-month low of $1.51 and a 12-month high of $12.00.

Insider Buying and Selling at AirSculpt Technologies

In related news, major shareholder Jorey Chernett acquired 105,848 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was purchased at an average price of $2.43 per share, with a total value of $257,210.64. Following the transaction, the insider owned 6,592,059 shares of the company's stock, valued at approximately $16,018,703.37. This trade represents a 1.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 810,150 shares of company stock worth $1,987,624. Company insiders own 44.60% of the company's stock.

Hedge Funds Weigh In On AirSculpt Technologies

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $30,000. XTX Topco Ltd boosted its position in shares of AirSculpt Technologies by 265.2% during the 4th quarter. XTX Topco Ltd now owns 179,813 shares of the company's stock worth $356,000 after purchasing an additional 130,581 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $219,000. Saba Capital Management L.P. purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $620,000. Finally, Millennium Management LLC purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 91.54% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of AirSculpt Technologies from a "sell" rating to a "hold" rating in a research note on Sunday, April 5th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, AirSculpt Technologies currently has an average rating of "Reduce" and a consensus price target of $6.00.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc NASDAQ: AIRS is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.